ReviewInternational journal of general medicine2021
Sex-Gender Differences in the Effectiveness of Treatment of Irritable Bowel Syndrome: A Systematic Review.
Review in International journal of general medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 4 syntheses or guidelines pooled it, 32 citations in OpenAlex.
- Gender Bias in Clinical Trials of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Type 2 Diabetes Mellitus: A Systematic Review.Journal of diabetes research · 2025Pooled it
- Fecal microbiota transplantation for irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials.Frontiers in immunology · 2023Pooled it
- Gender bias in clinical trials of biological agents for migraine: A systematic review.PloS one · 2023Pooled it
- Evaluating the Efficacy of Probiotics in IBS Treatment Using a Systematic Review of Clinical Trials and Multi-Criteria Decision Analysis.Nutrients · 2022Pooled it
- A Randomized Waitlist-Controlled Trial of a Positive Psychology Intervention for Irritable Bowel Syndrome: The WISH Proof-of-Concept Trial.Neurogastroenterology and motility · 2025Trial
- Perceived Utility of Cognitive Behavioral Therapy in People With Bowel Disorders of Gut-Brain Interaction.Neurogastroenterology and motility · 2026Article
- Divergent intestinal barrier and neuroimmune responses to supervised exercise across fibromyalgia, irritable bowel syndrome, and their comorbidity phenotypes: a prospective interventional study.Frontiers in physiology · 2026Article
- It's a Women's World: A New Look at Sex Differences in Patients with the Irritable Bowel Syndrome.Digestive diseases and sciences · 2025Article
- Brain Morphometry and Cognitive Features in the Prediction of Irritable Bowel Syndrome.Diagnostics (Basel, Switzerland) · 2025Article
- Positive Outcomes of Supplementation with Lecithin-Based Delivery Formulation ofLife (Basel, Switzerland) · 2024Article
- Lower urinary dysfunction as a long-term effect of childhood vincristine treatment, with potential influences by sex and dose.Scientific reports · 2024Article
- Review
- Efficacy of Quadruple-coated Probiotics in Patients With Irritable Bowel Syndrome: A Randomized, Double-blind, Placebo-controlled, Parallel-group Study.Journal of neurogastroenterology and motility · 2024Article
- Symptom management needs of patients with irritable bowel syndrome and concurrent anxiety and/or depression: A qualitative study.Journal of advanced nursing · 2023Article
- Pain in irritable bowel syndrome: Does anything really help?Neurogastroenterology and motility · 2022Review
- Gender-specific association between the regular use of statins and the risk of irritable bowel syndrome: A population-based prospective cohort study.Frontiers in pharmacology · 2022Article
- Sex-Bias in Irritable Bowel Syndrome: Linking Steroids to the Gut-Brain Axis.Frontiers in endocrinology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn recent years, research on sex-gender differences in health care has increasingly recognized that men and women differ in the way symptoms occur, in risk factors for certain conditions and in the way they respond to the same treatment. A disease that is known to often present differently in women and men is irritable bowel syndrome (IBS). Given the difference in prevalence, predominant symptoms and possible other pathophysiology, it is conceivable that a difference in treatment effectiveness in men and women is a discovery waiting to be found. PURPOSE: To determine whether there are differences in treatment effectiveness between men and women with irritable bowel syndrome. MATERIALS AND
methodsWe searched on PubMed and EMBASE, selecting randomized controlled trials comparing IBS treatment in men and women over 18 years old. One researcher performed the inclusion process, and two researchers independently performed a quality assessment. A descriptive analysis was conducted.
resultsTwelve studies, randomizing 1847 men and 3562 women, were included in this review. Treatment with serotonin antagonist alosetron, treatment with ibodutant and crofelemer and adding cognitive behavioral therapy to medical treatment found significant differences between men and women in favor of effectiveness towards women in either satisfactory relief of overall IBS symptoms or percentage of pain-free days.
conclusionSex-gender can be a determining factor in the effectiveness of IBS treatment. Due to the limited number of studies per treatment option, no recommendations can be made on the choice of a specific treatment. It is clear, however, that so as not to miss beneficial treatment options for either sex, the inclusion, analysis and description of data on the basis of sex is of the utmost importance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.